Regeneron Pharmaceuticals, Inc. $REGN Stock Position Reduced by Candriam S.C.A.

Candriam S.C.A. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.2% in the 1st quarter, Holdings Channel.com reports. The fund owned 186,388 shares of the biopharmaceutical company’s stock after selling 18,944 shares during the period. Regeneron Pharmaceuticals makes up 0.7% of Candriam S.C.A.’s investment portfolio, making the stock its 24th largest position. Candriam S.C.A.’s holdings in Regeneron Pharmaceuticals were worth $144,011,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in REGN. Nordea Investment Management AB lifted its holdings in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after buying an additional 74,350 shares during the period. Lockheed Martin Investment Management Co. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $2,702,000. Asio Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $3,422,000. Robeco Institutional Asset Management B.V. boosted its position in shares of Regeneron Pharmaceuticals by 116.6% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after purchasing an additional 140,966 shares in the last quarter. Finally, AE Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 36.7% in the 4th quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company’s stock worth $4,226,000 after purchasing an additional 1,470 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 0.5%

NASDAQ REGN opened at $664.52 on Friday. The firm’s 50 day moving average price is $645.30 and its two-hundred day moving average price is $722.39. The stock has a market cap of $70.25 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.47 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.22 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.33 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REGN. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $900.00 to $700.00 in a report on Monday, May 18th. Leerink Partners reissued a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $787.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.